Year-End Report 2019
ChromoGenics increases its business volume and completes preferential share issue for SEK 100.6 million, guaranteed to 75 percent, for accelerated growthFourth quarter of 2019 · Net sales for the period amounted to SEK 8.1 (6.8) million and earnings to SEK -23.2 (-22.9) million, which corresponds to earnings per share of SEK -0.06 (-0.53). Deliveries of backlogged customer orders for dynamic products were delayed during the quarter, which has meant that net sales have been postponed. · Gross profit amounted to SEK -6.5 million, which is a decrease of SEK -1.6 million compared to the